Sign in
Taking people in United StatesPhase 2

Tests AGuIX nanoparticles with radiation for brain metastases

Tests whether AGuIX nanoparticles plus radiation help adults with brain cancer spread.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the 2 sites
Trial code
Registry title
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Status
Recruiting
Phase
Phase 2
People taking part
134 people, planned
Started
15 Sept 2021
Expected to end
May 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Stereotactic Radiation
  • AGuIX gadolinium-based nanoparticles
  • Placebo
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with brain metastases from a solid cancer that are harder to control with stereotactic radiation alone. They get radiation with AGuIX nanoparticles or with a placebo.

Age
18 years or older at the time brain metastases were diagnosed.
Sex
All sexes can join.
Disease stage
Proven solid cancer with at least one brain metastasis of 5mm or more, plus one extra feature: melanoma growing despite immunotherapy, a gastrointestinal cancer, HER2-positive breast cancer, a cystic metastasis, a metastasis of 2cm (0.8 in) or more, or a metastasis that came back after earlier brain radiation.
Earlier treatment
Melanoma, gastrointestinal, HER2-positive breast, cystic or 2cm-or (0.8 in)-larger metastases that came back after earlier brain radiation can only join the groups that allow prior radiation. Anyone with prior brain radiation needs written approval from the study doctor.
Biomarker or test result
HER2-positive for the breast cancer group. Kidney function (estimated glomerular filtration rate) of at least 60 mL/min/1.73m2.

Main reasons for not taking part

  • Cannot have a brain MRI or cannot receive gadolinium
  • Widespread, definite leptomeningeal disease
  • Needs radiation to more than 10 targets (more than 20 if whole brain radiation was given before)
  • Pregnant or breastfeeding
  • Karnofsky performance status below 70, or expected survival under 3 months from the cancer outside the brain

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Participants must have a biopsy proven solid malignancy and at least one intracranial measurable lesion spanning ≥5mm in maximal unidimensional size and radiographically consistent with or pathologically proven to be a brain metastasis AND meet one of the following additional criteria regarding the primary site or nature of the intracranial disease:; Melanoma with intracranial growth consistent with tumor progression despite immunotherapy; Gastrointestinal primary; HER2 positive breast cancer (subtype assessed using most representative tissue available in opinion of enrolling clinician and/or study PI); Cystic metastases; Metastases ≥2cm in maximal unidimensional size; Locally recurrent metastases after prior stereotactic radiation; Locally recurrent metastases after prior whole brain radiation *Patients with metastases from melanoma, GI primaries, or HER2+ breast cancer, as well as those with cystic metastases or metastases ≥2cm in maximal unidimensional size, who have local recurrences after prior brain-directed radiation can only be treated in the strata permitting prior radiation (last two strata above)
  • Age ≥18 years at diagnosis of brain metastases
  • Estimated glomerular filtration rate of ≥ 60 mL/min/1.73m2
  • Karnofsky performance status of at least 70 (i.e. at minimum, "cares for self" but "unable to carry on normal activity or do active work")
  • Estimated survival based on extracranial disease of at least 3 months in the opinion of the enrolling clinician and/or study PI
  • Ability to understand and the willingness to sign a written informed consent document
  • The effects of AGuIX on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of the therapeutic component of study participation

Who cannot take part

  • Patients requiring radiation to either >10 targets (if naïve to whole brain radiation) or >20 targets (if whole brain radiation has been given previously) per the discretion of the treating clinician and/or study PI
  • In cohorts who have received prior brain-directed radiation, patients are not eligible for this study if they have active (at the time of protocol screening) brain metastases that require radiation that are in or within 1.0cm of the brainstem, eyes, optic nerves, or optic chiasm if the juxtaposed organ at risk (i.e. brainstem, eyes, optic nerves, or optic chiasm) has previously received either >6.0 Gy in a single fraction or, if prior radiation was fractionated, a cumulative dose in 2.0 Gy equivalents, using an alpha/beta ratio of 2, of >40.0 Gy. In addition, all patients who have had prior brain-directed radiation, regardless of technique/dose/fractionation, are not eligible for the study until written approval is provided by the study/site PI
  • Participants with widespread, definitive leptomeningeal disease
  • Participants who cannot undergo a brain MRI
  • Participants who cannot receive gadolinium
  • Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. Because there is an unknown but potential risk for adverse events in nursing infants, women who are breastfeeding are not eligible for this study

Where in United States

  • Brigham and Women's HospitalBoston, United StatesContact: Ayal AizerTaking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Ayal Aizer, MD, MPHTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

The 2 groups in the trial

  • Stereotactic Radiation plus AGuIX gadolinium-based nanoparticlesTreatment being tested

    Randomly assigned participants will receive: * AGuIX gadolinium-based nanoparticles 3-5 days before radiation is initiated * AGuIX gadolinium-based up to 2x during radiation, depending on standard of care radiation treatment. * If standard of care radiation treatment involves only one day of radiation, participant will receive AGuIX gadolinium-based nanoparticles on the day of radiation. * If standard of care radiation treatment involves 5 or 6 days of radiation, participant will receive AGuIX gadolinium-based nanoparticles two-times (2x) in total, on the first and third day of radiation.

    Treatment: Stereotactic Radiation and AGuIX gadolinium-based nanoparticles

  • Stereotactic Radiation plus placeboTreatment being tested

    Randomly assigned participants will receive: * Placebo 3-5 days before radiation is initiated * Placebo up to 2x during radiation, depending on standard of care radiation treatment. * If standard of care radiation treatment involves only one day of radiation participant will receive Placebo on the day of radiation. * If standard of care radiation treatment involves 5 or 6 days of radiation participant will receive Placebo two-times (2x) in total, on the first and third day of radiation.

    Treatment: Stereotactic Radiation and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone
Plain-language title
Tests AGuIX nanoparticles with radiation for brain metastasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
9 September 2026